

# Identify clinical trials meeting their endpoints

## Cortellis Clinical Trials Intelligence

When analyzing competitor trials, it's important to identify which factors may have contributed to meeting their endpoints and understand the clinical trials design and protocols followed. Which endpoints and biomarkers were included? What was the patient segmentation? How could future trials be redesigned if needed, to meet endpoints and save time and money?

This guide explains how Cortellis can help you identify clinical trials meeting their points in just a few clicks.

**Example:** Find Hepatitis C clinical trials meeting their endpoints and identify endpoints, biomarkers and patient segmentation included.

- Go to 'Clinical Trials' form in Advanced Search and enter the condition of interest, e.g. Hepatitis C virus infection.
- Add 'Phase' as a new field, select 'Phase 3 Clinical', 'Phase 3a Clinical' and 'Phase 3b Clinical' and click 'Search'.

Advanced Search - Clinical Trials

Search Strategy (non-editable)

Condition ( Hepatitis C virus infection )

AND Phase ( Phase 3 Clinical OR Phase 3a Clinical OR Phase 3b Clinical )

Drugs Patents Literature Clinical Trials Regulatory Deals

Condition Hepatitis C virus infection X

AND Phase Phase 3 Clinical OR Phase 3a Clinical OR Phase 3b Clinical X

AND Select

Add an additional search field

Reset SEARCH

- Once in the results page, click 'Filters' button in any of the columns to retrieve filter menu.
- Scroll down, go to 'Endpoints Met' and select 'Yes', as shown below.

Results Per page: 25 Sort by: Relevance Order Columns View

| Title                                                 | Condition                                                   | Patient Segment                                           | All Endpoints                                  | Recruitment Status | Phase            |
|-------------------------------------------------------|-------------------------------------------------------------|-----------------------------------------------------------|------------------------------------------------|--------------------|------------------|
| Study Comparing a DTaP-HB-PRP-T Combined Vaccine With | borrelia pertussis infection; Clostridium tetani infection; | DTaP vaccine - Subjects with Prior Vaccination - Subjects | DTaP vaccine - Assessment of Immune Response - | Completed          | Phase 3 Clinical |

SHOW ALL FILTERS

Secondary Endpoints

Results Available

**Endpoints Met**

Adverse Events

Added Date

Last Change Date

Unspecified (124)  
 Yes (114)  
 No (10)

Cancel Apply


- The search results table displays phase 3 clinical trials studying Hepatitis C meeting their endpoints.

114 results found for 'Condition ( Hepatitis C virus infection ) AND Phase ( Phase 3 Clinical or Phase 3a Clinical or Phase 3b Clinical ) ' with filter(s) applied: Yes

Results Per page: 25 Sort by: Relevance Order Columns View

| Title                                                                                                                                                    | Condition                   | Patient Segment                                                                                                                                                                                        | All Endpoints                                                                                                                                                                                                                       | Recruitment Status | Phase            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------------|
| <a href="#">An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC-435 as Part of a Treatment Regimen for Hepatitis C Infected Patients</a> | Hepatitis C virus infection | Hepatitis C virus infection - Subjects Infected with HCV Genotype 1; Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection; Hepatitis C virus infection - Treatment Naive Subjects | Hepatitis C virus infection - Analysis of Hepatitis C Virus Variants; Hepatitis C virus infection - Assessment of Fatigue - Assessment by Fatigue Severity Scale (FSS); Hepatitis C virus infection - Assessment of Liver Functions | Completed          | Phase 3 Clinical |

- Visualize the top endpoints and get the big picture by changing the view to 'Rank by' (top right icon, as shown below).
- Select 'All Endpoints' under Y axis menu and click 'Go'.



Note: Y axis can also display biomarkers, patient segmentation and other fields.

- View underlying information on trials including a specific endpoint by clicking the relevant bar in the chart. For example, click 'Assessment of Sustained Virologic Response (SVR)' to identify patient stratification, biomarkers and additional endpoints included in hepatitis C trials.

111 results found for 'Condition ( Hepatitis C virus infection ) AND Phase ( Phase 3 Clinical or Phase 3a Clinical or Phase 3b Clinical ) ' with filter(s) applied: Hepatitis C virus infection - Assessment of Sustained Virologic Response (SVR); Yes

Results Per page: 25 Sort by: End Date Most Recent Order Columns View

| Title                                                                                                                                                                                            | Condition                                                | Patient Segment                                                                                                                                                                                                                    | All Endpoints                                                                                                                                                                                                                | Recruitment Status | Phase             |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-------------------|
| <a href="#">EXPEDITION-8: A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1 to 6 Infection and Compensated Cirrhosis</a> | Compensated liver cirrhosis; Hepatitis C virus infection | Hepatitis C virus infection - Subjects Infected with HCV Genotype 1; Hepatitis C virus infection - Subjects Infected with HCV Genotype 2/3; Hepatitis C virus infection - Subjects Infected with HCV Genotype 4; Hepatitis C virus | Hepatitis C virus infection - Assessment of Safety and Tolerability; Hepatitis C virus infection - Assessment of Sustained Virologic Response (SVR); Hepatitis C virus infection - Assessment of Viral Breakthrough/Relapse; | Completed          | Phase 3b Clinical |

- Find out more details by clicking the trial's title to navigate to clinical trial report and read about trials arms, results, patient segmentation, biomarkers as well as specific primary and secondary endpoints.

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1 to 6 Infection and Compensated Cirrhosis

Snapshot [Highlight](#)  [Search Terms & Synonyms](#) [< Previous](#) [Next >](#)

Protocol & Results

Subjects & Measurements

- Eligibility Criteria
- **Outcome Measures**
- Patient Segmentation
- Biomarkers

Registry Contacts & Sites

Change History

Sources

OUTCOME MEASURES

[Expand all](#)

Primary(4)

| Measure                                                                                                                                                                                                                                                                                                                                                                                            | Time                                           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|
| Percentage of participants with sustained virological response 12 weeks post-treatment (SVR12) in hepatitis C virus (HCV) genotype (GT) 1, 2, 4, 5 and 6-infected participants in the per protocol (PP) population: SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (< LLOQ) 12 weeks after the last dose of study drug | 12 weeks after last dose of study drug         |
| Percentage of participants with SVR12 in HCV GT 1, 2, 4, 5 and 6-infected participants in the intent-to-treat (ITT) population: SVR12 was defined as HCV RNA level < LLOQ 12 weeks after the last dose of study drug in the ITT population                                                                                                                                                         | 12 weeks after last dose of study drug         |
| The primary efficacy variable is the percentage of subjects who achieve SVR12 (HCV RNA < LLOQ 12 weeks after the last actual dose of study drug) across genotypes                                                                                                                                                                                                                                  | 12 weeks following the last dose of study drug |
| Determine baseline polymorphisms and resistance associated amino acid substitutions (RAS) at time of failure in NS3 and NS5A                                                                                                                                                                                                                                                                       |                                                |

Secondary(5)

Outcome Measure Index

PATIENT SEGMENTATION

- Hepatitis C virus infection
  - Subjects with Chronic Hepatitis C Infection
  - Subjects with comorbid conditions
    - Subjects co-morbid with cirrhosis
  - Treatment Naive Subjects
  - Subjects with Compensated Liver Disease
  - Subjects Infected with HCV Genotype 1
    - Total Bilirubin > 3.0 mg/dl

To find out what's included in your subscription, contact your Clarivate account manager or [LS Product Support](#).